Biofrontera Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 111/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biofrontera Inc's Score
Industry at a Glance
Industry Ranking
111 / 158
Overall Ranking
311 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+628.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biofrontera Inc Highlights
StrengthsRisks
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.16% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.32M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 37.32M.
Fairly Valued
The company’s latest PE is -0.51, at a medium 3-year percentile range.
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Ticker SymbolBFRI
CompanyBiofrontera Inc
CEOLuebbert (Hermann)
Websitehttps://www.biofrontera-us.com/
FAQs
What is the current price of Biofrontera Inc (BFRI)?
The current price of Biofrontera Inc (BFRI) is 0.766.
What is the symbol of Biofrontera Inc?
The ticker symbol of Biofrontera Inc is BFRI.
What is the 52-week high of Biofrontera Inc?
The 52-week high of Biofrontera Inc is 1.870.
What is the 52-week low of Biofrontera Inc?
The 52-week low of Biofrontera Inc is 0.536.
What is the market capitalization of Biofrontera Inc?
The market capitalization of Biofrontera Inc is 8.92M.
What is the net income of Biofrontera Inc?
The net income of Biofrontera Inc is -17.76M.
Is Biofrontera Inc (BFRI) currently rated as Buy, Hold, or Sell?
According to analysts, Biofrontera Inc (BFRI) has an overall rating of Buy, with a price target of 6.000.
What is the Earnings Per Share (EPS TTM) of Biofrontera Inc (BFRI)?
The Earnings Per Share (EPS TTM) of Biofrontera Inc (BFRI) is -1.506.